Cetuximab (Erbitux®) Plus Radiation Boosts Survival for Patients with Head and Neck Cancer
3/21/2005 National Cancer Institute Clinical Trial Results As reported at the American Society of Clinical Oncology annual meeting, New Orleans, LA, [...]
If you didn't find what you were looking for, try a new search!
3/21/2005 National Cancer Institute Clinical Trial Results As reported at the American Society of Clinical Oncology annual meeting, New Orleans, LA, [...]
Source: upi.com Author: Allen Cone Treating HPV-positive throat cancer with cetuximab and radiation had worse overall and progression-free survival results compared [...]
Source: www.curetoday.com Author: Lauren M. Green The immunotherapy Keytruda (pembrolizumab), in a recent study, proved twice as effective for the treatment [...]
Source: medpagetoday.comAuthor: Charles Bankhead, Staff Writer, MedPage TodayDate: March 05, 2013 The addition of targeted agents to standard chemotherapy failed [...]
Source: The Oncology Report The Food and Drug Administration on Nov. 7 approved cetuximab as an initial treatment of late-stage head [...]
Source: MedScape News Today The US Food and Drug Administration (FDA) has approved cetuximab (Erbitux, Bristol-Myers Squibb ) for use in [...]
Source: www.medpagetoday.com Author: Michael Smith, North American Correspondent, MedPage Today A novel antibody improved outcomes for patients with advanced and inoperable [...]
Source: ESPN.com Author: Rick Reilly DAY 17: Tuesday, March 9, 7:30 a.m. -- Denver Nuggets coach George Karl pops in his [...]
Source: Drugs.com Author: Staff • Results inconsistent with data from all Erbitux pivotal studies • Further analyses planned by the Medical [...]
Source: www.newswise.com Author: staff The strategy of using monoclonal antibodies for cancer treatment was first described in the late 1970s with [...]
Source: professional.cancerconsultants.com Author: staff Researchers from the National Cancer Institute and the University of Chicago have reported that the combination of [...]
Source: www.docguide.com Author: staff The European Commission has approved a new indication for the use of cetuximab (Erbitux) to include first-line [...]
5/21/2008 Robert Langreth Forbes.com ImClone Systems' breakthrough colon cancer drug Erbitux has become a billion-dollar best seller as a one-size-fits-all drug [...]
6/3/2007 New York, NY staff Forbes.com Advances in treating lung and head/neck cancers could have immediate implications for patients, new research [...]
2/12/2007 California, USA Daniel Borenstein ContraCostaTimes.com (Note: This is the fourth of a four part series) About 9:45 each morning for [...]